UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

  

FORM 8-K

  

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): April 17, 2013 (April 11, 2013)

  

 

PLURISTEM THERAPEUTICS INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Nevada

(State or Other Jurisdiction of Incorporation)

 

001-31392   98-0351734
(Commission File Number)   (IRS Employer Identification No.)

 

MATAM Advanced Technology Park

Building No. 5

Haifa, Israel

   31905
(Address of Principal Executive Offices)   (Zip Code)

 

011 972 74 710 7171

(Registrant’s Telephone Number, Including Area Code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

Item 8.01. Other Events.

 

On April 11, 2013, the registrant announced that United Therapeutics Corporation received approval to perform a human Phase I study in Australia using the registrant’s PLacental eXpanded cells in patients diagnosed with Pulmonary Arterial Hypertension.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PLURISTEM THERAPEUTICS INC.
   
   
Date: April 17, 2013 By: /s/ Yaky Yanay
  Name: Yaky Yanay
  Title: Chief Financial Officer

 

 

2